Healthy Skepticism Library
Items where at least one author is a Healthy Skepticism member
HSL1418
Jureidini J, Tonkin A.
Paroxetine in major depression.
J Am Acad Child Adolesc Psychiatry 2003 May;42:(5):514
http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0890-8567&volume=42&issue=5&spage=514
HSL1233
Cassels A, Hughes MA, Cole C, Mintzes B, Lexchin J, McCormack JP.
Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs.
CMAJ 2003 Apr 29;168:(9):1133-7
http://www.cmaj.ca/cgi/content/full/168/9/1133
HSL1415
Jureidini JN, Tonkin AL.
Clinical practice guidelines for depression in young people.
Med J Aust 2003 Mar 17;178:(6):300
http://www.mja.com.au/public/issues/178_06_170303/letters_170303-5.html
HSL1188
Mansfield PR, Lexchin J, Vitry A, Doecke CJ, Svensson S.
Drug advertising in medical journals.
Lancet 2003 Mar 8;361:(9360):879
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T1B-48400HM-1B&_coverDate=03%2F08%2F2003&_alid=272642718&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=4886&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=fa10917712438764944ab5277ec07357
HSL5591
Russell FM, Shann F, Curtis N, Mulholland K.
Evidence on the use of paracetamol in febrile children.
Bull World Health Organ 2003;81:(5):367-72
http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0042-96862003000500011&lng=en&nrm=iso&tlng=en
HSL2256
Jureidini J, Mansfield PR.
Avoiding competing interests
BMJ 2002 Dec 27;325:(7377):1375
http://bmj.com/cgi/eletters/325/7377/1375
HSL1920
Vitry AI, Hurley E.
The road to consensus: considerations for the safe use and prescribing of COX-2-specific inhibitors.
Med J Aust 2002 Nov 18;177:(10):572-3
http://www.mja.com.au/public/issues/177_10_181102/vitry_181102.html
HSL1419
Jureidini J.
Does the International Consensus Statement on ADHD leave room for healthy scepticism?
Eur Child Adolesc Psychiatry 2002 Oct;11:(5):240
HSL1892
Molloy W, Strang D, Guyatt G, Lexchin J, Bedard M, Dubois S, Russo R.
Assessing the quality of drug detailing.
J Clin Epidemiol 2002 Aug;55:(8):825-32
HSL17906
Moynihan R
Celebrity selling
BMJ 2002 Jun 1;324:(7349):1342
http://www.bmj.com/cgi/content/citation/324/7349/1342?HITS=10&hits=10&stored;_search=&author1=Moynihan%2C%2BR&maxtoshow;=&FIRSTINDEX=0&resourcetype=1,2,3,4,10&searchid=1023661467365_9984&RESULTFORMAT;=
HSL5849
Toop L, Richards D.
DTCA in New Zealand: the challenge of finding an acceptable balance
Br J Gen Pract. 2002 Apr 1;52:(477):341
HSL5592
Shann F.
Research in developing countries.
N Engl J Med 2002 Feb 21;346:(8):627-8
HSL27
Mintzes B, Barer ML, Kravitz RL, Kazanjian A, Bassett K, Lexchin J, et al.
Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey
BMJ 2002;324:278-279
http://bmj.bmjjournals.com/cgi/content/full/324/7332/278
HSL2148
WHO Department of Essential Drugs & Medicines Policy
Drug Promotion Database
: WHO Department of Essential Drugs & Medicines Policy 2002
http://www.drugpromo.info/
HSL13290
Lexchin J, Mintzes B.
Direct-to-Consumer Advertising of Prescription Drugs: The Evidence Says No
Journal of Public Policy and Marketing 2002;21:(2):194-201
http://web.archive.org/web/20080511145449/http://www.marketingpower.com/content18627.php
HSL5593
Shann F.
Uses of error: the wrong research costs lives.
Lancet 2001 May 26;357:(9269):1691
http://linkinghub.elsevier.com/retrieve/pii/S0140673600048790
HSL34
Vlassov V, Mansfield P, Lexchin J, Vlassova A.
Do drug advertisements in Russian medical journals provide essential information for safe prescribing?
West J Med 2001;174:391-394
HSL2156
Jureidini J, Mansfield P.
Does drug promotion adversely influence doctors’ abilities to make the best decisions for patients?
Australasian Psychiatry 2001;9:95-99
http://www.blackwell-synergy.com/doi/full/10.1046/j.1440-1665.2001.00313.x?prevSearch=allfield%3A%28Jureidini+J+and+Mansfield+P%29
HSL6960
Gifts: a transcript of a television report
MaLAM International News 2000 Sep-Oct;18:(9-10):1-4
HSL19762
Mansfield P
Sickening sales pitch of the drug marketeers
The Sydney Morning Herald 2000 July 3
http://newsstore.smh.com.au/apps/viewDocument.ac?page=1&sy=smh&kw=Sickening+sales+pitch+of+the+drug&pb=smh&dt=selectRange&dr=entire&so=relevance&sf=text&sf=headline&rc=10&rm=200&sp=nrm&clsPage=1&docID=news000703_0087_8149
HSL856
Irwig LM, Loy CT, Chapman S, Glasziou PP, Mansfield PR, Salkeld GP, Walton MM.
!nform test kits distributed with the MJA.
Med J Aust 2000 May 15;172:(10):518-9
HSL2242
Roughead L, Semple S, Vitry A.
The Value of Pharmacist Professional Services in the Community: A systematic review of the literature 1990-2002
2000
HSL20171
Mansfield P
Debate: drug advertising: No
Australian Doctor 1999 Oct 864
HSL1032
Lexchin J.
Don't bite the hand that feeds you.
West J Med 1999 Oct;171:(4):238-9
http://www.pubmedcentral.gov/articlerender.fcgi?tool=pubmed&pubmedid=10578675
HSL6891
Memoirs of methods used to sell drugs
MaLAM International News 1999 Mar-Apr;17:(3-4):1-6
HSL6888
Advertising of antibacterials
Health Skepticism 1999 Feb;2:(2):1-5
HSL6886
Advertising of CCBs for hypertension
Health Skepticism 1999 Jan;2:(1):3-4
HSL394
Lexchin J.
Drug not considered a first-line agent.
Can Fam Physician 1998 Nov;44:2376
HSL6832
ACE inhibitors
Health Skepticism 1998 Nov;1:(1):3-4
HSL396
Lexchin J.
Intellectual property rights and drug prices.
Lancet 1998 Aug 15;352:(9127):582
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T1B-4FWV34C-NC&_coverDate=08%2F15%2F1998&_alid=305534210&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=4886&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=85140d6e65b19947f465cc4160cdcac0
HSL393
Lexchin J.
Residents and pharmaceutical representatives.
Can Fam Physician 1998 Jul;44:1448:
HSL6816
MaLAM letter follow up—MaLAM apologises but we remain concerned about thepromotion of Atarax
MaLAM International News 1998 Jul-Aug;16:(7-8):1-5
HSL20519
Sweet M
New fears on doctors' links to drug firms
The Sydney Morning Herald 1998 Jan 233
HSL395
Lexchin J.
Improving the appropriateness of physician prescribing.
Int J Health Serv 1998;28:(2):253-67
HSL1550
Mansfield PR.
MaLAM, a medical lobby for appropriate marketing of pharmaceuticals.
Med J Aust 1997 Dec 1-15;167:(11-12):590-2
http://www.mja.com.au/public/issues/xmas/mansfield/mansfield.html
HSL6776
Mansfield P, Vitry A.
Re: the promotion of prescription products in Australia
1997 Dec;
HSL418
Vitry A, Mansfield P.
Drug advertisements in medical journals.
Lancet 1997 Nov 15;350:(9089):1477-8
http://www.thelancet.com/search/results?search_searchuri=%2Fsearch%2Fadvanced&search_resulturi=%2Fsearch%2Fresults&search_preview=no&search_reqfirst=1&search_reqcount=20&search_submode=advanced&update_search=no&search_mode=platform&search_cluster=phoenix&search_text1=Vitry+A&search_within1=au&search_operator1=and&search_text2=Mansfield+P&search_within2=au&search_operator2=and&search_text3=advertisements&search_within3=ti&restrictterm_lancet=lancet&restrictname_lancet=lancet&restricttype_lancet=journal&restrictdesc_lancet=The+Lancet&restrictname_laneur=laneur&restricttype_laneur=journal&restrictdesc_laneur=The+Lancet+Neurology&restrictname_laninf=laninf&restricttype_laninf=journal&restrictdesc_laninf=The+Lancet+Infectious+Diseases&restrictname_lanonc=lanonc&restricttype_lanonc=journal&restrictdesc_lanonc=The+Lancet+Oncology&search_dateradio=combo&search_datecombo=0%3AALL&search_monthstartcombo=1&search_yearstart=1996&search_monthendcombo=1&search_yearend=2005&search_wordsexactly=yes&search_sort=relevance&Submit=Search
HSL545
Lexchin J.
Code of marketing practices.Voluntary self-regulation for the Pharmaceutical Manufacturers Association of Canada
Can Fam Physician. 1997 11 01;43:
HSL1894
Lexchin J.
What information do physicians receive from pharmaceutical representatives?
Can Fam Physician 1997 May;43:941-5
HSL392
Lexchin J.
[Pharmaceutic regulation and inadequate drug prescription in Canada: the case of psychotropic drugs in the 1960s and early 1970s]
Sante Ment Que. 1997 Spring;22:(1):283-300
HSL547
Lexchin J.
Enforcement of codes governing pharmaceutical promotion: what happens when companies breach advertising guidelines?
CMAJ 1997 Feb 1;156:(3):351-6
http://www.cmaj.ca/cgi/reprint/156/3/351
HSL520
Shear NH, Black F, Lexchin J.
Physician-detailer interaction—II.
Can J Clin Pharmacol 1997;4:(1):10
HSL538
Mansfield P, Lexchin J.
MaLAM: networking for scientific integrity in drug promotion.
Essential Drugs Monitor 1997(24):5
http://web.archive.org/web/20080511183432/http://healthyskepticism.org/library/EDM/24/Page5.pdf
HSL539
Mansfield P.
Can health professionals lobby drug companies to upgrade from misleading promotion to reliable service?
Australian Prescriber 1997;20:(Supp 1):150
HSL546
Lexchin J.
Recent progress in drug advertising
Can Fam Physician 1997;43:1041-1042
HSL585
Vitry A, Mansfield P.
Promotion of Coversyl by Servier.
Lancet 1996 May 18;347:(9012):1411
HSL639
Anderson GM, Lexchin J.
Strategies for improving prescribing practice.
CMAJ 1996 Apr 1;154:(7):1013-7
http://www.cma.ca/cmaj/vol-154/1013e.htm
HSL586
Vitry A.
Pharmaceutical promotion: drug advertising affects your prescribing
Australian Prescriber 1996;19:103
HSL594
Shear NH, Black F, Lexchin J.
Examining the physician-detailer interaction
Can J Clin Pharmacol 1996;3:(4):175-179
HSL609
Lexchin J.
Direct to consumer advertising of prescription drugs: the next steps
Can J Clin Pharmacol 1996;3:(2):65
HSL364
Lexchin J.
Deception by design: Pharmaceutical promotion in the Third World
Penang: Consumers International 1995
HSL667
Lexchin J.
Is there a bias in industry supported clinical research
Can J Clin Pharmacol 1995;2:15-18
HSL6149
Lexchin J.
Agents against pediatric diarrhea. Assessing the information companies supply to Canadian physicians
Can Fam Physician. 1994 Dec 01;40:2082-7
HSL6155
Mansfield PR.
MaLAM: encouraging trustworthy drug promotion
Essential Drugs Monitor 1994;(17):6
HSL2157
Lexchin J.
Interactions between physicians and the pharmaceutical industry: what does the literature say?
CMAJ 1993 Nov 15;149:(10):1401-7
http://www.cmaj.ca/cgi/content/abstract/149/10/1401?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&author1=Lexchin+J&andorexactfulltext=and&searchid=1124491359271_2918&stored_search=&FIRSTINDEX=0&sortspec=relevance&resourcetype=1&journalcode=cmaj
HSL5164
Lexchin J.
Physicians and drug companies interact.
Can Fam Physician 1993 Sep 01;39:1881-2
HSL4641
Re: the promotion of aspirin
1992 Nov 1;
HSL3984
Wade VA, Mansfield PR, McDonald PJ.
Drug companies' evidence to justify advertising.
Lancet 1989 Nov 25;2:(8674):1261-3
HSL857
Mansfield PR.
Drug advertising.
Lancet 1989 May 20;1:(8647):1137-8
HSL2055
Mansfield PR.
Drug Advertising
Med J Aust 1987 Jun 15;146:(12):660-661
HSL861
Mansfield P.
Phenylbutazone.
Med J Aust 1986 Jan 6;144:(1):55
HSL20475
Mansfield PR
Phenylbutazone
Medical Journal of Australia 1986 Jan 6;144:55
HSL862
Mansfield P.
Phenylbutazone.
Med J Aust 1985 Sep 2;143:(5):219-20
HSL20483
MLAM
Round the World: From our Correspondents: Australia: MLAM
Lancet 1984 Oct 13;861
HSL19755
Lexchin J.
Lifestyle drugs: issues for debate.
CMAJ 2001 15;164:(10):1449-51
http://www.cmaj.ca/content/164/10/1449.long
HSL19873
Mansfield P
Pushing expensive new drugs
Consuming Interest 2001 00 00;
HSL19874
Mansfield P
Pushing expensive new drugs
Consuming Interest 20010
HSL20469
Mansfield PR
Drug Marketing in the Third World
National News The Royal College of General Practitioners 1984 Aug
HSL20476
Ideas for Action: MLAM
New Internationalist 1984 Apr29
http://newint.org/features/1984/04/05/action/
HSL20480
Protecting The Innocent From Harm: The Medical Lobby for Appropriate Marketing (MLAM)
New Doctor ?198522, 23
